Showing results (1-10 of 257) with videos related to
Sort By:
Pageof 26
Expert Review of Clinical Pharmacology|June 13, 2015
Strategies to overcome resistance to tyrosine kinase inhibitors in non-small-cell lung cancerMariacarmela Santarpia, Nuno Gil, Rafael RosellExpert Review of Respiratory Medicine|February 6, 2015
Alectinib: a selective, next-generation ALK inhibitor for treatment of ALK-rearranged non-small-cell lung cancerMariacarmela Santarpia, Giuseppe Altavilla, Rafael RosellExpert Opinion on Emerging Drugs|September 19, 2007
Emerging drugs for non-small-cell lung cancerEnriqueta Felip, Mariacarmela Santarpia, Rafael RosellFuture Oncology (London, England)|April 3, 2015
Personalized treatment of early-stage non-small-cell lung cancer: the challenging role of EGFR inhibitorsMariacarmela Santarpia, Giuseppe Altavilla, Vincenzo Pitini, et al.Expert Opinion on Investigational Drugs|December 15, 2022
'Why is survival with triple negative breast cancer so low? insights and talking points from preclinical and clinical research'Maria Ilenia Passalacqua, Graziella Rizzo, Mariacarmela Santarpia, et al.Current Opinion in Pharmacology|June 13, 2006
Predicting the outcome of chemotherapy for lung cancerRafael Rosell, Fabiana Cecere, Mariacarmela Santarpia, et al.Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|April 25, 2006
From the bench to the bed: individualizing treatment in non-small-cell lung cancerMariacarmela Santarpia, Giuseppe Altavilla, Fernanda Salazar, et al.Journal of Thoracic Disease|July 10, 2020
Mechanisms of resistance to osimertinibChiara Lazzari, Vanesa Gregorc, Niki Karachaliou, et al.Urology Case Reports|October 26, 2020
Capillary leak syndrome induced by neoadjuvant cisplatin and gemcitabine in a patient with bladder cancerMarco Massafra, Maria Ilenia Passalacqua, Giuseppe Lupo, et al.International Journal of Cancer|November 19, 2016
KRAS driven expression signature has prognostic power superior to mutation status in non-small cell lung cancerÁdám Nagy, Lőrinc Sándor Pongor, András Szabó, et al.Pageof 26